Literature DB >> 33490882

Dexamethasone acutely suppresses the anabolic SNAT2/SLC38A2 amino acid transporter protein in L6-G8C5 rat skeletal muscle cells.

Safia Blbas1, Emma Watson2, Heather Butler3, Jeremy Brown2, Terence P Herbert4, Cordula M Stover1, Alan Bevington1, Nima Abbasian1.   

Abstract

Chronic metabolic acidosis plays a role in cachexia by enhancing total proteolysis in skeletal muscle. Glucocorticoid also triggers proteolysis and plays a permissive role in the effect of acidosis. The System A amino acid transporter SNAT2/SLC38A2 is ubiquitously expressed in mammalian cells including muscle, performing Na+-dependent active import of neutral amino acids, and is strongly inhibited by low pH. Exposure of rat skeletal muscle cell line L6-G8C5 to low pH rapidly inhibits SNAT2 transport activity and enhances total proteolysis rate. Pharmacological inhibition or silencing of SNAT2 also enhances proteolysis. This study tests the hypothesis that the glucocorticoid dexamethasone (DEX), like low pH, inhibits SNAT2 activity in L6-G8C5 myotubes, thus contributing to total proteolysis. Incubation with 500 nM DEX for 4 h reduced the System A amino acid transport rate to half the rate in control cultures. This inhibition depended on glucocorticoid receptor-mediated gene transcription, but SNAT2 mRNA levels were unaffected by DEX. In contrast, the SNAT2 protein assessed by immunoblotting was significantly depleted. The co-inhibitory effects of DEX and low pH on System A transport activity were additive in stimulating total proteolysis. In keeping with this mechanism, DEX's inhibitory effect on SNAT2 transport activity was significantly blunted by the proteasome inhibitor MG132. Proof of principle was achieved in similar experiments using recombinant expression of a GFP-tagged SNAT2 fusion protein in HEK293A cells. It is concluded that DEX acutely depletes the SNAT2 transporter protein, at least partly through proteasome-dependent degradation of this functionally important transporter.
© 2020 The Authors. FASEB BioAdvances published by the Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  SLC38A2; SNAT2; dexamethasone; glucocorticoid; skeletal muscle; ubiquitin‐proteasome pathway

Year:  2020        PMID: 33490882      PMCID: PMC7805547          DOI: 10.1096/fba.2020-00076

Source DB:  PubMed          Journal:  FASEB Bioadv        ISSN: 2573-9832


  58 in total

1.  Impaired glycolysis and protein catabolism induced by acid in L6 rat muscle cells.

Authors:  A Bevington; J Brown; A Pratt; J Messer; J Walls
Journal:  Eur J Clin Invest       Date:  1998-11       Impact factor: 4.686

2.  Systemic inflammation is associated with exaggerated skeletal muscle protein catabolism in maintenance hemodialysis patients.

Authors:  Serpil M Deger; Adriana M Hung; Jorge L Gamboa; Edward D Siew; Charles D Ellis; Cindy Booker; Feng Sha; Haiming Li; Aihua Bian; Thomas G Stewart; Roy Zent; William E Mitch; Naji N Abumrad; T Alp Ikizler
Journal:  JCI Insight       Date:  2017-11-16

Review 3.  Metabolic Acidosis and Subclinical Metabolic Acidosis in CKD.

Authors:  Kalani L Raphael
Journal:  J Am Soc Nephrol       Date:  2017-10-13       Impact factor: 10.121

4.  Neutralization of Western diet inhibits bone resorption independently of K intake and reduces cortisol secretion in humans.

Authors:  Marc Maurer; Walter Riesen; Juergen Muser; Henry N Hulter; Reto Krapf
Journal:  Am J Physiol Renal Physiol       Date:  2002-09-24

5.  Stimulation of protein degradation by low pH in L6G8C5 skeletal muscle cells is independent of apoptosis but dependent on differentiation state.

Authors:  Warren Pickering; Mai-Kim Cheng; Jeremy Brown; Heather Butler; John Walls; Alan Bevington
Journal:  Nephrol Dial Transplant       Date:  2003-08       Impact factor: 5.992

6.  Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes.

Authors:  Michael Menconi; Patricia Gonnella; Victoria Petkova; Stewart Lecker; Per-Olof Hasselgren
Journal:  J Cell Biochem       Date:  2008-10-01       Impact factor: 4.429

Review 7.  Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects.

Authors:  Helgi B Schiöth; Sahar Roshanbin; Maria G A Hägglund; Robert Fredriksson
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

8.  Proteasomal modulation of cellular SNAT2 (SLC38A2) abundance and function by unsaturated fatty acid availability.

Authors:  Francesca Nardi; Thorsten M Hoffmann; Clare Stretton; Emma Cwiklinski; Peter M Taylor; Harinder S Hundal
Journal:  J Biol Chem       Date:  2015-02-04       Impact factor: 5.157

9.  Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer.

Authors:  Matteo Morotti; Esther Bridges; Alessandro Valli; Hani Choudhry; Helen Sheldon; Simon Wigfield; Nicki Gray; Christos E Zois; Fiona Grimm; Dylan Jones; Eugene J Teoh; Wei-Chen Cheng; Simon Lord; Dimitrios Anastasiou; Syed Haider; Alan McIntyre; Deborah C I Goberdhan; Francesca Buffa; Adrian L Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-31       Impact factor: 11.205

Review 10.  The association of physical function and physical activity with all-cause mortality and adverse clinical outcomes in nondialysis chronic kidney disease: a systematic review.

Authors:  Heather J MacKinnon; Thomas J Wilkinson; Amy L Clarke; Douglas W Gould; Thomas F O'Sullivan; Soteris Xenophontos; Emma L Watson; Sally J Singh; Alice C Smith
Journal:  Ther Adv Chronic Dis       Date:  2018-07-04       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.